Viracta Therapeutics IncNASDAQ:VIRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2018
- TODAY'S CHANGE (%)-0.0032 (-1.5610%)
- Bid / Lots0.1950/ 10
- Ask / Lots0.2050/ 1
- Open / Previous Close0.2008 / 0.2050
- Day Range
- 52 Week Range
- Volume486,804
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VIRX |
|---|---|---|
| 09:32 ET | 3688 | 0.2008 |
| 09:34 ET | 26244 | 0.204 |
| 09:36 ET | 1500 | 0.20489 |
| 09:39 ET | 19736 | 0.2034 |
| 09:48 ET | 2690 | 0.206 |
| 09:50 ET | 5237 | 0.2041 |
| 09:52 ET | 2400 | 0.2023 |
| 09:54 ET | 100 | 0.204086 |
| 09:56 ET | 204 | 0.2023 |
| 09:57 ET | 5255 | 0.204 |
| 09:59 ET | 179 | 0.2031 |
| 10:01 ET | 6726 | 0.2001 |
| 10:03 ET | 1470 | 0.2004 |
| 10:06 ET | 6354 | 0.2 |
| 10:08 ET | 84207 | 0.1954 |
| 10:12 ET | 6000 | 0.1965 |
| 10:14 ET | 7454 | 0.1986 |
| 10:15 ET | 10000 | 0.1975 |
| 10:17 ET | 1306 | 0.1975 |
| 10:19 ET | 6429 | 0.1955 |
| 10:21 ET | 7744 | 0.1955 |
| 10:28 ET | 100 | 0.1974 |
| 10:30 ET | 12912 | 0.1975 |
| 10:32 ET | 1000 | 0.1975 |
| 10:33 ET | 800 | 0.1975 |
| 10:35 ET | 5000 | 0.1975 |
| 10:37 ET | 800 | 0.1997 |
| 10:42 ET | 503 | 0.2 |
| 10:44 ET | 12736 | 0.2024 |
| 10:46 ET | 3639 | 0.2024 |
| 10:57 ET | 3300 | 0.2 |
| 11:00 ET | 8676 | 0.2063 |
| 11:04 ET | 4950 | 0.200101 |
| 11:06 ET | 5100 | 0.2 |
| 11:08 ET | 200 | 0.203 |
| 11:22 ET | 250 | 0.203 |
| 11:27 ET | 5635 | 0.2 |
| 11:33 ET | 29364 | 0.195 |
| 11:36 ET | 3000 | 0.195 |
| 11:42 ET | 500 | 0.1952 |
| 11:44 ET | 26984 | 0.1951 |
| 11:47 ET | 4700 | 0.1994 |
| 12:00 ET | 100 | 0.1952 |
| 12:02 ET | 12500 | 0.1951 |
| 12:03 ET | 20000 | 0.2001 |
| 12:14 ET | 1128 | 0.2001 |
| 12:16 ET | 111 | 0.1952 |
| 12:23 ET | 1044 | 0.1953 |
| 12:36 ET | 2640 | 0.1953 |
| 12:38 ET | 5000 | 0.2037 |
| 12:41 ET | 250 | 0.1995 |
| 12:48 ET | 1205 | 0.1995 |
| 12:50 ET | 795 | 0.1954 |
| 12:57 ET | 270 | 0.1979 |
| 01:03 ET | 200 | 0.203 |
| 01:21 ET | 365 | 0.203699 |
| 01:26 ET | 100 | 0.203 |
| 01:30 ET | 400 | 0.2 |
| 01:48 ET | 1000 | 0.2 |
| 01:50 ET | 140 | 0.2 |
| 01:51 ET | 100 | 0.2 |
| 02:00 ET | 200 | 0.2 |
| 02:15 ET | 250 | 0.20289 |
| 02:36 ET | 300 | 0.20195 |
| 02:42 ET | 500 | 0.2029 |
| 02:45 ET | 2537 | 0.201 |
| 02:49 ET | 200 | 0.2014 |
| 02:54 ET | 100 | 0.2016 |
| 03:00 ET | 295 | 0.2017 |
| 03:02 ET | 2350 | 0.20165 |
| 03:05 ET | 4000 | 0.2017 |
| 03:07 ET | 855 | 0.2016 |
| 03:09 ET | 200 | 0.2016 |
| 03:14 ET | 248 | 0.201 |
| 03:16 ET | 3711 | 0.2016 |
| 03:36 ET | 1303 | 0.2016 |
| 03:38 ET | 300 | 0.2017 |
| 03:50 ET | 4000 | 0.204 |
| 03:57 ET | 1119 | 0.200101 |
| 03:59 ET | 4873 | 0.2018 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Viracta Therapeutics Inc | 8.1M | -0.2x | --- |
Cyclerion Therapeutics Inc | 8.1M | -0.7x | --- |
Bioxytran Inc | 7.8M | -4.8x | --- |
Virpax Pharmaceuticals Inc | 8.4M | -0.1x | --- |
Alterola Biotech Inc | 7.7M | -3.2x | --- |
NLS Pharmaceutics AG | 7.6M | -0.5x | --- |
Company Information
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Contact Information
- Headquarters
- 2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA, CA, United States 92007
- Phone
- 858-400-8470
- Fax
- 650-266-3501
Executives
- Independent Chairman of the Board
- Roger Pomerantz
- President, Chief Executive Officer, Director
- Mark Rothera
- Chief Financial Officer
- Michael Faerm
- Senior Vice President - Finance
- Melody Burcar
- Chief Medical Officer
- Darrel Cohen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.71 |
EPS | $-1.16 |
Book Value | $0.47 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
